Welcome to our dedicated page for CBLI news (Ticker: cbli), a resource for investors and traders seeking the latest updates and insights on CBLI stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CBLI's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CBLI's position in the market.
Cleveland BioLabs, Inc. (NASDAQ: CBLI) announced that its SEC Form S-4 Registration Statement for its merger with Cytocom Inc. was declared effective on June 10, 2021. A virtual Special Meeting for stockholders to approve the merger will occur on July 6, 2021. Upon closing, the combined company will be named Cytocom Inc., trading under the symbol 'CYTO' on NASDAQ. The merger is contingent on stockholder approval and customary closing conditions. Cleveland BioLabs aims to enhance its immunotherapy capabilities through this strategic partnership, targeting significant medical needs.
Genome Protection, Inc. has published findings on GP532, a novel deimmunized Toll-like receptor 5 (TLR5) agonist, in Communications Biology. This preclinical study showcases GP532's enhanced efficacy for treating acute radiation syndrome (ARS) and potential long-term applications in various diseases. Unlike its predecessor, entolimod, GP532's effectiveness is not hindered by human antibodies. A $3M grant from the US Department of Defense supports its development for idiopathic pulmonary fibrosis (IPF). This advancement signals promising growth for Cleveland BioLabs, Inc. (NASDAQ:CBLI).
Cleveland BioLabs (NASDAQ:CBLI) has successfully completed a registered direct offering, selling 2,000,000 shares of common stock at a price of $7.00 per share, grossing $14 million. The net proceeds will be used for general corporate purposes. The offering was facilitated by H.C. Wainwright & Co. under an effective registration statement with the SEC. The company focuses on developing innovative treatments targeting serious medical needs, including radiation sickness and cancer treatments.
Cleveland BioLabs (NASDAQ: CBLI) has announced a registered direct offering of 2,000,000 shares at $7.00 per share, aiming to raise approximately $14 million. The offering, arranged by H.C. Wainwright & Co., is expected to close around February 23, 2021, pending customary conditions. The proceeds will be used for general corporate purposes. The shares are offered under an effective registration statement filed with the SEC. This offering may impact shareholder equity due to potential dilution.
Cleveland BioLabs (NASDAQ: CBLI) has filed a Registration Statement on Form S-4 with the SEC, linked to its merger with Cytocom, Inc. Expected to finalize in Q2 2021, this merger aims to create a unified biopharmaceutical entity. Post-merger, legacy Cleveland BioLabs shareholders will hold approximately 39% of outstanding shares, while Cytocom shareholders will possess about 61%. This strategic combination is anticipated to enhance growth opportunities for the new Cytocom, as it integrates both companies' innovative therapies targeting immune-related conditions.
Cytocom, Inc., a biopharmaceutical firm specializing in immune therapies, announced its participation in two significant virtual events: Biotech Showcase Digital from January 11-15, 2021, and H.C. Wainwright BioConnect 2021 from January 11-14, 2021, during J.P. Morgan's Healthcare Conference week. Company management will engage in one-on-one meetings with investors to discuss its lead compounds, CYTO-201 for Crohn's disease and CYTO-401 for pancreatic cancer, which are set to enter Phase 3 trials in 2021. Cytocom aims to leverage its unique immunotherapy platform for various diseases.
Cytocom, Inc. announced a merger with Cleveland BioLabs, Inc. (NASDAQ: CBLI) in a letter from CEO Michael K. Handley, dated October 21, 2020. This all-stock transaction, approved by both companies' Boards and majority shareholders, is set to close in Q1 2021, creating a new Cytocom listed on Nasdaq under the symbol "CYTO." The merger aims to enhance Cytocom's pipeline, including clinical trials for major diseases. Additionally, the acquisition of ImQuest Life Sciences is expected to strengthen drug development capabilities, benefiting both companies' shareholders.
Cytocom and Cleveland BioLabs have announced a definitive merger agreement, forming a combined entity listed on Nasdaq. This all-stock transaction will grant Cytocom shareholders a majority position in the new company. The merger aims to leverage both companies' strengths in immune-modulating therapies to address significant medical needs, with a focus on oncology, infectious diseases, and more. The transaction is expected to close in Q1 2021, pending stockholder approval and customary conditions. A conference call is scheduled for October 28 to discuss the merger further.
Cytocom, Inc. and Cleveland BioLabs have announced a definitive merger agreement to create a single public company focusing on developing immunotherapies for various serious medical conditions. The all-stock transaction will result in Cytocom shareholders holding a majority in the newly formed entity, which intends to remain listed on Nasdaq. This merger is expected to produce significant commercial opportunities in areas like oncology and infectious diseases, with multiple milestones anticipated within 12 to 18 months. The transaction is expected to close in Q1 2021, pending approval by Cleveland BioLabs' stockholders.
